Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin P, Salgado C, Hansen I, Durup D, et al. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin P, Salgado C, Hansen I, Durup D, et al.
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Majority of physicians treated patient with at least 1 drug-resistant infection
    63% of surveyed infectious disease physicians treated a patient with at least one drug-resistant infection in 2011. 56% believed those infections to be on the rise.  
  • Enormous annual direct cost of HAIs to hospitals
    The annual direct cost of healthcare-associated infections to U.S. hospitals ranges from $28.4 billion to $45 billion.  
  • MRSA infections increase in older patients
    In 2008, 75% of healthcare-associated invasive MRSA infections occurred in patients older than 50, with 46% in patients older than 65%.  
  • 75% of c. diff infections start in places like nursing homes and physician offices
    75% of clostridium difficile (C. difficile) infections, a common HAI, start in places like nursing homes and physician offices.  
  • ~70% of hospital HAIs resistant to ≥ antimicrobial
    Approximately 70% of hospital-acquired HAIs are resistant to at least one antimicrobial drug.